

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-46. (Canceled)

47. (Previously Presented) A nucleic acid molecule encoding an amino acid sequence consisting of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5.

48. (Previously Presented) A vector comprising the nucleic acid of claim 47.

49. (Previously Presented) The vector of claim 48, wherein the vector is selected from the group consisting of *E. coli* plasmid, *Listeria* vector, orthopox virus, avipox virus, capripox virus, suipox virus, vaccinia virus, baculovirus, human adenovirus, SV40 virus and bovine papilloma virus.

50. (Previously Presented) The vector of claim 49 further comprising a nucleotide sequence encoding at least one HLA class I molecule.

51. (Canceled)

52. (Previously Presented) A kit comprising the vector of claim 48.

53. (Currently Amended) A kit comprising

(a) a CEA agonist peptide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5 and

(b) a vector comprising a gene encoding CEA ~~or a recombinantly produced CEA protein~~ and an immunostimulatory molecule selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, interferon gamma, tumor necrosis factor alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, CD72, and cyclophosphamide.

54. (Previously Presented) The kit according to claim 53, wherein said agonist peptide is SEQ ID NO: 2.

55. (Canceled)

56. (Previously Presented) The vector of claim 50, wherein the HLA class I molecule is HLA-A2.

57. (Canceled)

58. (Previously Presented) A composition comprising the nucleic acid molecule of claim 47.

59. (Previously Presented) The composition of claim 58, which is capable of stimulating a CEA specific cytolytic cytotoxic T lymphocyte (CTL) response in a subject.